SCHEMBL16675670

SCHEMBL16675670

CCOC(=O)N(C)CC(c1ccc(OC)cc1)C1(OC)CCCCC1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 12/20 0.51
SLC6A4 P31645 11/20 0.51
SLC6A3 Q01959 10/20 0.51
LMNA P02545 1/20 0.51
CNR1 P21554 1/20 0.51
HTR2A P28223 1/20 0.51
HRH1 P35367 1/20 0.51
HRH3 Q9Y5N1 1/20 0.51
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
CACNA1F O60840 1/20 0.38
CACNA1D Q01668 1/20 0.38
CACNA1S Q13698 1/20 0.38
CACNA1C Q13936 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6392452 0.81 SLC6A2 (0.71) SLC6A2SLC6A4SLC6A3LMNACNR1
SCHEMBL16675666 0.79 SLC6A2 (0.57) SLC6A2SLC6A4SLC6A3LMNACNR1
SCHEMBL6707041 0.75 SLC6A2 (0.62) SLC6A2SLC6A4SLC6A3LMNACNR1
SCHEMBL3994041 0.75 SLC6A2 (0.66) SLC6A2SLC6A4SLC6A3LMNACNR1
Hydrochloric Acid SCHEMBL6709072 0.74 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3LMNACNR1
Hydrochloric Acid SCHEMBL6707426 0.74 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3LMNACNR1
Hydrochloric Acid SCHEMBL6707673 0.74 SLC6A2 (0.66) SLC6A2SLC6A4SLC6A3LMNACNR1
SCHEMBL16100233 0.73 SLC6A2 (0.71) SLC6A2SLC6A4SLC6A3LMNACNR1
SCHEMBL5971689 0.73 SLC6A2 (0.60) SLC6A2SLC6A4SLC6A3LMNACNR1
SCHEMBL3406789 0.73 SLC6A2 (0.62) SLC6A2SLC6A4SLC6A3LMNACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9399634-B2 Compositions and methods for the treatment of depression CELLIX BIO PRIVATE LIMITED (IN) 2016-07-26 US disclosed
US-9399634-B2 Compositions and methods for the treatment of depression CELLIX BIO PRIVATE LIMITED (IN) 2016-07-26 US disclosed
US-20150119453-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION CELLIX BIO PRIVATE LIMITED (IN) 2015-04-30 US disclosed
US-20150119453-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION CELLIX BIO PRIVATE LIMITED (IN) 2015-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119453-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION BRCA1, APC, MSH2 SLC6A2 95/4885SLC6A4 19/4885SLC6A3 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.